BOLD — Boundless Bio Income Statement
0.000.00%
Last trade - 00:00Annual income statement for Boundless Bio, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | 2025 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | PROSPECTUS/A | PROSPECTUS/A | PROSPECTUS/A | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Total Revenue | 0 | 0 | 0 | 0 | 0 |
| Selling / General / Administrative Expenses | |||||
| Research And Development | |||||
| Total Operating Expenses | 25.3 | 46.5 | 54.8 | 73.3 | 63.6 |
| Operating Profit | -25.3 | -46.5 | -54.8 | -73.3 | -63.6 |
| Total Net Non Operating Interest Income / Expense | |||||
| Other Net Non Operating Costs | |||||
| Net Income Before Taxes | -25.2 | -45.9 | -49.4 | -65.4 | -58.2 |
| Net Income After Taxes | -25.2 | -45.9 | -49.4 | -65.4 | -58.2 |
| Net Income Before Extraordinary Items | |||||
| Net Income | -25.2 | -45.9 | -49.4 | -65.4 | -58.2 |
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Diluted Net Income | -25.2 | -45.9 | -49.4 | -65.4 | -58.2 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | -1.13 | -2.06 | -2.22 | -3.85 | -2.6 |
| Dividends per Share |